- Home
- EHAB vs PRTA Comparison
EHAB vs PRTA Comparison
Compare EHAB & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- PRTA
- Stock Information
- Founded
- EHAB 2014
- PRTA 2012
- Country
- EHAB United States
- PRTA Ireland
- Employees
- EHAB N/A
- PRTA N/A
- Industry
- EHAB Hospital/Nursing Management
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- PRTA Health Care
- Exchange
- EHAB Nasdaq
- PRTA Nasdaq
- Market Cap
- EHAB 409.1M
- PRTA 472.1M
- IPO Year
- EHAB N/A
- PRTA N/A
- Fundamental
- Price
- EHAB $7.60
- PRTA $8.16
- Analyst Decision
- EHAB Buy
- PRTA Buy
- Analyst Count
- EHAB 3
- PRTA 10
- Target Price
- EHAB $8.67
- PRTA $12.29
- AVG Volume (30 Days)
- EHAB 385.0K
- PRTA 901.1K
- Earning Date
- EHAB 11-05-2025
- PRTA 11-11-2025
- Dividend Yield
- EHAB N/A
- PRTA N/A
- EPS Growth
- EHAB N/A
- PRTA N/A
- EPS
- EHAB N/A
- PRTA N/A
- Revenue
- EHAB $1,037,800,000.00
- PRTA $10,341,000.00
- Revenue This Year
- EHAB $4.95
- PRTA N/A
- Revenue Next Year
- EHAB $4.33
- PRTA $602.32
- P/E Ratio
- EHAB N/A
- PRTA N/A
- Revenue Growth
- EHAB N/A
- PRTA N/A
- 52 Week Low
- EHAB $6.47
- PRTA $4.32
- 52 Week High
- EHAB $10.91
- PRTA $22.71
- Technical
- Relative Strength Index (RSI)
- EHAB 44.79
- PRTA 51.85
- Support Level
- EHAB $7.57
- PRTA N/A
- Resistance Level
- EHAB $8.16
- PRTA $8.50
- Average True Range (ATR)
- EHAB 0.23
- PRTA 0.31
- MACD
- EHAB -0.04
- PRTA -0.39
- Stochastic Oscillator
- EHAB 11.11
- PRTA 93.47
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.